Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seattle Genetics Inc (SGEN)

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,180,336
  • Shares Outstanding, K 173,102
  • Annual Sales, $ 916,710 K
  • Annual Income, $ -158,650 K
  • 60-Month Beta 1.46
  • Price/Sales 34.21
  • Price/Cash Flow N/A
  • Price/Book 17.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.63
  • Number of Estimates 9
  • High Estimate -0.29
  • Low Estimate -0.96
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -162.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
147.20 +18.44%
on 06/12/20
182.97 -4.71%
on 07/09/20
+17.65 (+11.26%)
since 06/10/20
3-Month
117.91 +47.87%
on 04/13/20
182.97 -4.71%
on 07/09/20
+54.03 (+44.91%)
since 04/09/20
52-Week
63.02 +176.66%
on 07/16/19
182.97 -4.71%
on 07/09/20
+108.10 (+163.17%)
since 07/10/19

Most Recent Stories

More News
Merck's Keytruda Gets Priority Review for Lymphoma Indication

FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.

PFE : 33.83 (+1.11%)
MRK : 76.73 (+0.05%)
GSK : 39.91 (-1.14%)
SGEN : 174.35 (-3.76%)
Shares of SGEN Up 61.1% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on March 26th, 2020 at $110.40. In approximately 4 months, Seattle Genetics has returned 61.10% as of today's recent price of $177.85....

SGEN : 174.35 (-3.76%)
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement,...

SGEN : 174.35 (-3.76%)
Look for Shares of Seattle Genetics to Potentially Pullback after Yesterday's 4.17% Rise

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $169.22 to a high of $178.13. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high...

SGEN : 174.35 (-3.76%)
Seattle Genetics' Adcetris Progresses Well Amid Competition

Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.

RHHBY : 44.2300 (-0.61%)
MRK : 76.73 (+0.05%)
BMY : 57.43 (-1.17%)
SGEN : 174.35 (-3.76%)
3 Top Biotech Stocks for July

The biotech sector is one of the obvious winners of the coronavirus. Amgen (AMGN), Vertex (VRTX), and Seattle Genetics (SGEN) are the top stock picks for July. A variety of startups and established...

AMGN : 249.04 (-1.04%)
SGEN : 174.35 (-3.76%)
VRTX : 294.45 (-0.32%)
XOMA Announces Natasha Hernday Joins its Board of Directors

XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, Inc., has joined the Company's Board of Directors. Ms. Hernday has...

AMGN : 249.04 (-1.04%)
SGEN : 174.35 (-3.76%)
XOMA : 19.08 (-1.40%)
SmarTrend Watching for Potential Pullback in Shares of Seattle Genetics After 1.23% Gain

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $164.09 to a high of $169.37. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high...

SGEN : 174.35 (-3.76%)
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks...

SGEN : 174.35 (-3.76%)
Nasdaq Continues to Excel : 5 Best Stocks in ETF

In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.

BMRN : 126.06 (-0.59%)
LRCX : 339.98 (+1.26%)
INCY : 104.76 (-2.88%)
SGEN : 174.35 (-3.76%)
QQQ : 263.97 (+0.68%)
ZM : 275.87 (+2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 183.52
1st Resistance Point 178.94
Last Price 174.35
1st Support Level 171.81
2nd Support Level 169.27

See More

52-Week High 182.97
Last Price 174.35
Fibonacci 61.8% 137.15
Fibonacci 50% 123.00
Fibonacci 38.2% 108.84
52-Week Low 63.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar